Drugs / Post-Transplant Cyclophosphamide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06252870 | Jul 2024 → Oct 2027 expected | graft versus host disease, hematopoietic and lymphoid cell neoplasm | Nantes University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06001385 | Dec 2023 → Feb 2026 overdue | acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia, chronic myelomonocytic leukemia +3 | Center for International Blood and Marrow Transplant Research | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Post-Transplant Cyclophosphamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06252870 ↗ |